Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group

The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influenced by the occurrence of progressive multifocal leukoencephalopathy (PML). Through measurement of the anti-JCV antibody index, and in combination with the presence or absence of other known risk factors, i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Neurol Neurosurg Psychiatry
Glavni autori: McGuigan, C, Craner, M, Guadagno, J, Kapoor, R, Mazibrada, G, Molyneux, P, Nicholas, R, Palace, J, Pearson, O R, Rog, D, Young, C A
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2016
Teme:
Multiple Sclerosis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4752634/
https://ncbi.nlm.nih.gov/pubmed/26492930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2015-311100
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items